Basilea Pharmaceutica BSLN

SWX: BSLN | ISIN: CH0011432447 27/06/2025

47,60 CHF (-0,83%)

(-0,83%) 27/06/2025

Grafiek Basilea Pharmaceutica

Grafiek Basilea Pharmaceutica

1 dag1d -0,83%
1 week1w -2,06%
1 maand1m 4,39%
3 maanden3m 5,66%
6 maanden6m 14,70%
1 jaar1j 20,51%
5 jaar5j -4,15%

Basilea Pharmaceutica in het nieuws

Toon enkel gratis nieuws

5 juni 2025 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea · Persbericht

20 mei 2025 · Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States · Persbericht

24 april 2025 · Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea · Persbericht

16 april 2025 · Basilea shareholders approve all proposals of the board of directors at the annual general meeting · Persbericht

16 april 2025 · Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025 · Persbericht

14 maart 2025 · Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea · Persbericht

18 februari 2025 · Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow · Persbericht

5 februari 2025 · Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea · Persbericht

28 januari 2025 · Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea · Persbericht

8 januari 2025 · Basilea provides portfolio update and outlook · Persbericht

Profiel Basilea Pharmaceutica

CEO: David Veitch

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe